Agefi – Dow Jones |
|
Pfizer confirms its entry into the capital of Valneva for 90.5 million euros | Photo credits: Valneva
PARIS (Agefi-Dow Jones)–The biotechnology company Valneva announced on Thursday that the American group Pfizer had made an investment of 90.5 million euros in the company, in accordance with the agreement announced earlier this week, and held 8.1% of the capital. “Valneva expects to use the proceeds of this investment to fund part of its contribution to the Phase 3 development program of the Lyme disease vaccine candidate VLA15. Pfizer expects to initiate the Phase 3 study of VLA15 in the third quarter. 2022,” the company said in a statement. ([email protected]) editor: ECH
Agefi-Dow Jones The financial newswire
Dow Jones Newswires
June 23, 2022 12:21 ET (16:21 GMT)